We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.29%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
-$325M
(-11%)
Cap. Flow
-$480M
Cap. Flow
% of AUM
-19.19%
Top 10 Holdings %
Top 10 Hldgs %
43.13%
Holding
114
New
31
Increased
17
Reduced
20
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$104M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$96.5M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$96.1M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$86.3M |
| 5 |
Natera
NTRA
|
+$80.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$115M |
| 2 |
Incyte
INCY
|
+$95.4M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$79.2M |
| 4 |
AbbVie
ABBV
|
+$78.9M |
| 5 |
IQVIA
IQV
|
+$77.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.3% |
| 2 | Consumer Discretionary | 4.43% |
| 3 | Real Estate | 2.56% |
| 4 | Financials | 1.86% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
CALL
Vertex Pharmaceuticals
VRTX
$121B
| $37.7M | 1.51% |
187,000
| – | – |
|
27
Welltower
WELL
$164B
| $36.1M | 1.44% |
434,590
-492,450
| -53% | -$37.7M |
|
28
HCA Healthcare
HCA
$85.7B
| $35.1M | 1.4% |
169,710
-245,280
| -59% | -$50M |
|
29
McKesson
MCK
$97.5B
| $30.7M | 1.23% |
160,760
-312,570
| -66% | -$60.4M |
|
30
Cencora
COR
$59.5B
| $30.3M | 1.21% |
264,340
-318,950
| -55% | -$37.7M |
|
31
Syndax Pharmaceuticals
SNDX
$1.73B
| $30.1M | 1.2% |
1,751,342
+379,862
| +28% | +$6.96M |
|
32
Halozyme
HALO
$9.84B
| $29.5M | 1.18% |
649,052
-96,553
| -13% | -$4.27M |
|
33
Ventas
VTR
$45.8B
| $28M | 1.12% |
489,640
-660,220
| -57% | -$36.9M |
|
34
Tenet Healthcare
THC
$20B
| $25.2M | 1.01% |
+376,180
| New | +$23.3M |
|
|
35
Vertex Pharmaceuticals
VRTX
$121B
| $23.8M | 0.95% |
117,960
-548,500
| -82% | -$115M |
|
|
36
CALL
Incyte
INCY
$24.1B
| $22.5M | 0.9% |
+267,000
| New | +$22.3M |
|
37
DexCom
DXCM
$32.8B
| $21.7M | 0.87% |
203,560
-364,880
| -64% | -$35M |
|
|
LGV
38
DELISTED
Longview Acquisition Corp. II
LGV
| $20.9M | 0.84% |
+2,135,900
| New | +$21M |
|
|
AFMD
39
DELISTED
Affimed
AFMD
| $20.6M | 0.82% |
242,296
+83,502
| +53% | +$7.62M |
|
40
Idexx Laboratories
IDXX
$46.4B
| $18.9M | 0.75% |
29,900
+11,490
| +62% | +$6.34M |
|
41
Cytokinetics
CYTK
$10.5B
| $14.8M | 0.59% |
749,310
+286,810
| +62% | +$6.73M |
|
|
DCPH
42
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $14.1M | 0.57% |
+386,190
| New | +$15M |
|
|
RACB
43
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $13.4M | 0.54% |
1,324,800
+324,800
| +32% | +$3.42M |
|
|
ARYD
44
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $13.3M | 0.53% |
1,238,881
+79,521
| +7% | +$847K |
|
45
LivaNova
LIVN
$4.54B
| $10.5M | 0.42% |
+125,000
| New | +$10.3M |
|
|
MSAC
46
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $7.18M | 0.29% |
+744,000
| New | +$7.27M |
|
47
Ironwood Pharmaceuticals
IRWD
$718M
| $6.73M | 0.27% |
522,712
-213,489
| -29% | -$2.44M |
|
|
RAPT
48
DELISTED
RAPT Therapeutics
RAPT
| $6.36M | 0.25% |
+25,000
| New | +$4.67M |
|
49
GH Research
GHRS
$1.99B
| $5.43M | 0.22% |
+250,000
| New | +$5.11M |
|
|
IMA
50
ImageneBio Inc
IMA
$65.1M
| $5.3M | 0.21% |
31,463
+3,029
| +11% | +$668K |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2021 Portfolio in Review
As of Q2 2021, HealthCor Management held 114 positions worth $2.5B, down 11% from $2.83B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
HealthCor Management withdrew a net $480M in Q2 2021, closing 42 positions and reducing 20 holdings. Its most notable exit was Incyte, an estimated $95.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Real Estate.
Against the trend, HealthCor Management opened a new position in CVS Health worth $106M.
- HealthCor Management's largest Q2 2021 buy was CVS Health: 1,267,330 shares worth $106M.
- HealthCor Management added most to Biogen in Q2 2021, an estimated $78.4M increase.
- HealthCor Management's biggest Q2 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $115M.
- HealthCor Management fully exited Incyte in Q2 2021, selling an estimated $95.4M.
- HealthCor Management's ten largest holdings make up 43% of its $2.5B portfolio in Q2 2021.
- HealthCor Management opened 31 new positions and closed 42 in Q2 2021.
- HealthCor Management's portfolio value fell 11% quarter-over-quarter to $2.5B.
Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.